Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Everolimus may help cytarabine and daunorubicin work better by making cancer cells
more sensitive to chemotherapy. Giving everolimus together with cytarabine and daunorubicin
may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when
given together with cytarabine and daunorubicin in treating patients with relapsed acute
myeloid leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Institut de Recherche Clinique sur les Cancers et le Sang